Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neo-RCC and Pembrolizumab in Advanced Renal Cell Carcinoma
NCT07686744Phase 1Not yet recruiting
- Sponsor
- Jian Lin
- Start
- Sep 2026
- Primary completion
- Jan 2029
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of personalized neoantigen polyepitope peptide vaccine in renal cell carcinoma (RCC), sponsored by Jian Lin. Primary endpoint: Treatment-Emergent Adverse Events at 24 weeks. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
personalized neoantigen polyepitope peptide vaccine
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT07686744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07686744.